Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
Interventions
- OTHER: Laboratory Biomarker Analysis
- BIOLOGICAL: Rilotumumab
Sponsor
Gynecologic Oncology Group
Collaborators